Heidelberg Pharma AG

  • WKN: A11QVV
  • ISIN: DE000A11QVV0
  • Land: Deutschland

Nachricht vom 06.11.2019 | 10:41

Heidelberg Pharma AG: Heidelberg Pharma Announces Participation at Various Conferences

DGAP-News: Heidelberg Pharma AG / Key word(s): Conference

06.11.2019 / 10:41
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Heidelberg Pharma Announces Participation at Various Conferences

Ladenburg, Germany, 6 November 2019 - Heidelberg Pharma AG (FSE: WL6) today announced that they will participate at the following investor events and scientific conferences. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.

BIO-Europe
Date: 11 - 13 November 2019
Venue: Hamburg Messe, Hamburg, Germany

10th Jefferies 2019 London Healthcare Conference
Date: 20 - 21 November 2019
Venue: Waldorf Hilton, London, UK

German Equity Forum 2019
Date: 25 - 27 November 2019
Venue: Sheraton Frankfurt Airport Hotel and Conference Center, Frankfurt am Main, Germany

Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma, will give a company presentation on Monday, 25 November 2019 at 02:30 pm CET in room Oslo.

PEGS Europe: The Essential Protein Engineering Summit
Date: 18 - 22 November 2019
Venue: Lisbon Congress Center, Lisbon, Portugal

Dr. George Badescu, Vice President Scientific Affairs of Heidelberg Pharma, will give the following presentation on Monday, 18 November 2019 at 02:45 pm UTC (03:45 pm CET):

Amanitin-Based Antibody-Drug Conjugates as New Therapeutic Modalities for Cancer Therapy

Information on the conference: https://www.pegsummiteurope.com

Furthermore, Heidelberg Pharma will publish research results of the MAGICBULLET project in a poster presentation.

Details of the presentation:

A New Small-Molecule-Drug-Conjugate Platform for Targeted Tumor Therapy: α-Amanitin-based Drug Conjugates Targeting PSMA
Session: Next Generation Antibody Drug Conjugates, Poster Session A
Presenter: Francesca Gallo, Barbara Korsak
Date: 18/19 November 2019
Room: Rio Pavilion

 

About Heidelberg Pharma's proprietary ATAC technology
Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

Contact
Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
E-Mail: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Mobil: +49 160 9360 3022
E-Mail: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.



06.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

UmweltBank AG mit deutlichem Kurspotenzial

Die UmweltBank AG, die als einzige Bank Deutschlands den Umweltgedanken in der Satzung verankert hat, präsentierte in den letzten Jahren beeindruckende Wachstumszahlen. Sowohl die Kundeneinlagen als auch das Kreditbuch legten um durchschnittlich gut 6,3 % zu. Seit seiner Gründung hat das Kreditinstitut stets positive Ergebnisse erzielt, zuletzt im Geschäftsjahr 2018 einen Jahresüberschuss in Höhe von 25,3 Mio. €. Wir haben ein Kursziel von 14,30 € je Aktie ermittelt, was deutlich oberhalb des aktuellen Kursniveaus liegt. Die Dividendenrendite liegt bei fast 3,0 %.

Aktueller Webcast

SeaChange Corporation

22nd Annual Needham Growth Conference

15. Januar 2020

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Reduzieren

20. Januar 2020